Parallel Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$216K Hold
10,078
﹤0.01% 1220
2026
Q1
$140K Buy
10,078
+9,379
+1,342% +$149K ﹤0.01% 1388
2025
Q4
$11.4K Hold
699
﹤0.01% 2555
2025
Q3
$10.5K Hold
699
﹤0.01% 2519
2025
Q2
$8.14K Buy
699
+234
+50% +$2.13K ﹤0.01% 2561
2025
Q1
$3.46K Hold
465
﹤0.01% 2809
2024
Q4
$2.79K Hold
465
﹤0.01% 2854
2024
Q3
$2.38K Hold
465
﹤0.01% 2848
2024
Q2
$1.68K Hold
465
﹤0.01% 2848
2024
Q1
$1.49K Sell
465
-21
-4% -$81 ﹤0.01% 2866
2023
Q4
$2.38K Sell
486
-260
-35% -$1.19K ﹤0.01% 2750
2023
Q3
$4.07K Sell
746
-243
-25% -$1.61K ﹤0.01% 2569
2023
Q2
$6.64K Sell
989
-343
-26% -$2.55K ﹤0.01% 2329
2023
Q1
$11.8K Buy
1,332
+186
+16% +$1.64K ﹤0.01% 2063
2022
Q4
$8.76K Buy
1,146
+252
+28% +$1.96K ﹤0.01% 2082
2022
Q3
$6K Buy
894
+79
+10% +$744 ﹤0.01% 2185
2022
Q2
$7K Buy
815
+301
+59% +$2.65K ﹤0.01% 2113
2022
Q1
$7K Buy
514
+29
+6% +$456 ﹤0.01% 2148
2021
Q4
$14K Buy
485
+15
+3% +$460 ﹤0.01% 1945
2021
Q3
$16K Hold
470
﹤0.01% 1836
2021
Q2
$19K Hold
470
﹤0.01% 1701
2021
Q1
$19K Buy
+470
New +$25.4K ﹤0.01% 1596

Other funds holding ADPT

Parallel Advisors's ADPT Position: Q2 2026 in Review

Parallel Advisors held its Adaptive Biotechnologies (ADPT) position steady in Q2 2026 at 10,078 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #1220.

Parallel Advisors first reported a position in ADPT in Q1 2021 and has held it in 22 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Parallel Advisors held 10,078 shares of Adaptive Biotechnologies worth $216K as of Q2 2026.
  • Parallel Advisors left its Adaptive Biotechnologies share count unchanged in Q2 2026.
  • Adaptive Biotechnologies made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1220 holding.
  • Parallel Advisors first reported a position in Adaptive Biotechnologies in Q1 2021 and has held it in 22 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.